Please assess the completion status of the following clinical trial:

Trial Title: Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 18-90 years of age~* Diagnosis of CLI~* Infrainguinal occlusive disease, without options for revascularization~* No surgical interventions planned~* Life expectancy of 2 years~* Normal organ and marrow function~* Patients with controlled blood pressure (≤ 180/110 mmHg) and established anti-hypertensive therapy~* Established anti-platelet therapy~Exclusion Criteria:~* Poorly controlled diabetes mellitus (hemoglobin A1c \[HbA1c\] \> 10%)~* Aortoiliac disease with \> 50% stenosis~* Wounds with severity greater than Grade 3 on the Wagner Scale~* Any known failed ipsilateral revascularization within 2 weeks of enrollment~* Previous amputation of the talus, or above in the target limb~* Life-threatening ventricular arrhythmia; unstable angina; or, myocardial infarction within 4 weeks of enrollment~* Severe congestive heart failure (CHF) (i.e. New York Heart Association \[NYHA\] Stage IV)~* Receiving treatment with hematopoietic growth factors~* Infection of the involved extremity(ies)~* Active wet gangrenous tissue~* Require uninterruptible anticoagulation therapy~* Blood clotting disorder~* Cancer~* End stage renal disease requiring dialysis for more than 6 months prior to enrollment~* Pregnant or lactating~* Having received medication for thrombolytic therapy (e.g. rTPA or other enzymatic clot busters) within 30 days prior to enrollment~* Undergoing hyperbaric oxygen treatment within 2 weeks of enrollment~* Concomitant wound treatments with growth factors or tissue engineered products~* Receiving anti-angiogenic drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Ixmyelocel-T (Type: EXPERIMENTAL): The treatment arm of the study will receive injections of the study cellular product.
- Placebo (Type: PLACEBO_COMPARATOR): The control arm of the study will receive placebo injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).